Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Press Releases
Biosimilars Council Press Releases
Press Releases
Press Releases
November 19, 2021
AAM
Association for Accessible Medicines Warns Build Back Better Act Threatens Patient Access
Press Releases
November 18, 2021
AAM
AAM Opposes Latest Prescription Drug Reform Framework
Press Releases
November 12, 2021
AAM
AAM Statement on the Nomination of Dr. Robert Califf to Lead FDA
Press Releases
November 10, 2021
AAM
Paula Witt Joins AAM as Senior Manager, State Government Affairs
Press Releases
November 4, 2021
AAM
Study Finds U.S. Generic and Biosimilar Savings Totaled A Record $338 Billion in 2020
Press Releases
October 31, 2021
AAM
Biosimilars Council Encourages Stakeholders, Advocates to Join #GlobalBiosimilarsWeek
Press Releases
October 27, 2021
AAM
Kenneth Westberry Joins AAM As Senior Manager, State Government Affairs
Press Releases
October 6, 2021
AAM
Christine Simmon Named Executive Vice President, Policy and Strategic Alliances for the Association for Accessible Medicines
Press Releases
September 24, 2021
AAM
Polly Webster Joins AAM As Vice President, Federal Affairs
Press Releases
September 13, 2021
AAM
Scott Kuzner Joins AAM As Senior Director, Sciences and Regulatory Affairs
Press Releases
September 9, 2021
AAM
AAM Statement on HHS 45-Day Plan to Lower the Cost of Prescription Drugs
Press Releases
August 16, 2021
AAM
AAM Calls for Increased Voluntary Licensing of Covid Vaccines to Increase Patient Access
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Commitment to Quality
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH